Comparing VolitionRx (NYSE:VNRX) and Myriad Genetics (NASDAQ:MYGN)
Comparing VolitionRx (NYSE:VNRX) and Myriad Genetics (NASDAQ:MYGN)
VolitionRx (NYSE:VNRX – Get Rating) and Myriad Genetics (NASDAQ:MYGN – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.
VolitionRx(NYSE：VNRX-GET Rating)和Myriad Genetics(納斯達克：MYGN-GET Rating)都是醫療公司，但哪隻股票更優越？我們將根據兩家公司的分析師建議、風險、估值、股息、盈利能力、收益和機構所有權的強弱對它們進行比較。
Volatility & Risk
波動性與風險
VolitionRx has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.
VolitionRx的貝塔係數為1.62，表明其股價的波動性比標準普爾500指數高出62%。相比之下，Myriad Genetics的貝塔係數為1.7，這表明其股價的波動性比標準普爾500指數高70%。
Valuation & Earnings
估值與收益
This table compares VolitionRx and Myriad Genetics' gross revenue, earnings per share (EPS) and valuation.
該表格比較了VolitionRx和Myriad Genetics的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VolitionRx | $90,000.00 | 1,254.17 | -$26.82 million | ($0.56) | -3.52 |
| Myriad Genetics | $690.60 million | 3.14 | -$27.20 million | ($0.24) | -112.12 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 誓言Rx | $90,000.00 | 1,254.17 | -2,682萬元 | ($0.56) | -3.52 |
| 無數種遺傳學 | 6.906億美元 | 3.14 | -2,720萬元 | ($0.24) | -112.12 |
Profitability
盈利能力
This table compares VolitionRx and Myriad Genetics' net margins, return on equity and return on assets.
下表比較了VolitionRx和Myriad Genetics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| VolitionRx | -15,698.45% | -226.46% | -107.31% |
| Myriad Genetics | -2.62% | -3.44% | -2.57% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 誓言Rx | -15,698.45% | -226.46% | -107.31% |
| 無數種遺傳學 | -2.62% | -3.44% | -2.57% |
Insider & Institutional Ownership
內部人與機構所有權
11.1% of VolitionRx shares are held by institutional investors. Comparatively, 97.4% of Myriad Genetics shares are held by institutional investors. 16.0% of VolitionRx shares are held by company insiders. Comparatively, 1.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
VolitionRx 11.1%的股份由機構投資者持有。相比之下，Myriad Genetics 97.4%的股份由機構投資者持有。VolitionRx 16.0%的股份由公司內部人士持有。相比之下，Myriad Genetics 1.8%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一隻股票的長期表現將好於大盤。
Analyst Ratings
分析師評級
This is a breakdown of current recommendations and price targets for VolitionRx and Myriad Genetics, as provided by MarketBeat.
這是MarketBeat提供的VolitionRx和Myriad Genetics的當前建議和目標價的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VolitionRx | 0 | 0 | 0 | 0 | N/A |
| Myriad Genetics | 1 | 1 | 0 | 0 | 1.50 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 誓言Rx | 0 | 0 | 0 | 0 | 不適用 |
| 無數種遺傳學 | 1 | 1 | 0 | 0 | 1.50 |
Myriad Genetics has a consensus target price of $28.33, indicating a potential upside of 5.29%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than VolitionRx.
Myriad Genetics的共識目標價為28.33美元，表明潛在上行5.29%。考慮到Myriad Genetics更有可能的上行空間，分析師們顯然認為Myriad Genetics比VolitionRx更有利。
Summary
摘要
Myriad Genetics beats VolitionRx on 8 of the 12 factors compared between the two stocks.
與VolitionRx相比，Myriad Genetics在12個因素中有8個擊敗了VolitionRx。
About VolitionRx
關於VolitionRx
(Get Rating)
(獲取評級)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VolitionRx有限公司是一家跨國表觀遺傳學公司，致力於開發血液測試，以幫助診斷全球範圍內的一系列癌症和其他疾病。它銷售檢測癌症的Nu.Q；監測免疫系統的Nu.Q Nets；用於獸醫應用的Nu.Q Vet癌症篩查測試；Nu.Q Capture捕獲和濃縮樣本以進行更準確的診斷；以及Nu.Q Discover，一種分析核小體的解決方案。該公司運營的是血液檢測技術平臺--核糖體。VolitionRx有限公司總部設在德克薩斯州奧斯汀。
About Myriad Genetics
關於Myriad Genetics
(Get Rating)
(獲取評級)
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics，Inc.是一家基因測試和精密藥物公司，在美國和國際上開發基因測試並將其商業化。該公司提供分子診斷測試，用於腫瘤學、婦女和心理健康應用。它提供了MyRisk遺傳性癌症測試，這是一種評估遺傳性癌症風險的DNA測序測試；BRAC分析CDX種系伴隨診斷測試，這是一種DNA測序測試，有助於確定轉移性乳腺癌、卵巢癌、轉移性胰腺癌或轉移性前列腺癌患者的治療方案，這些患者具有有害或疑似有害的種系BRCA變異；以及MyChoice CDX伴生診斷測試，這是一種腫瘤測試，可以確定卵巢癌患者的同源重組缺陷狀態。該公司還提供Prolaris前列腺癌預後測試，這是一種評估前列腺癌侵襲性的RNA表達腫瘤分析；EndoPredict乳腺癌預後測試，這是一種評估乳腺癌侵襲性的RNA表達測試；Prequel Tumor，一種精確腫瘤學的解決方案；以及Prequel Prenatus Screen，一種使用母體血液進行的非侵入性產前篩查測試，以篩查胎兒中的嚴重染色體疾病。此外，它還提供Foresight Carrier Screen，這是一種為未來父母提供的產前測試，以評估他們將隱性遺傳疾病遺傳給後代的風險；以及GeneSight精神病精神健康藥物測試，這是一種DNA基因分型測試，可幫助患有抑鬱症、焦慮症、ADHD和其他精神健康疾病的患者選擇精神藥物。Myriad Genetics，Inc.與Illumina，Inc.和InterMountain Precision Gentics公司建立了戰略合作關係，提供生殖系和體細胞腫瘤檢測服務。該公司成立於1991年，總部設在猶他州鹽湖城。
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收VolitionRx日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對VolitionRx和相關公司的最新新聞和分析師評級的每日簡要摘要。